These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24259627)

  • 1. Dosing considerations for obese patients receiving cancer chemotherapeutic agents.
    Hall RG; Jean GW; Sigler M; Shah S
    Ann Pharmacother; 2013 Dec; 47(12):1666-74. PubMed ID: 24259627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
    Andriguetti NB; Raymundo S; Antunes MV; Perassolo MS; Verza SG; Suyenaga ES; Linden R
    Curr Med Chem; 2017; 24(33):3559-3582. PubMed ID: 28641556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
    Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
    Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
    Sparreboom A; Wolff AC; Mathijssen RH; Chatelut E; Rowinsky EK; Verweij J; Baker SD
    J Clin Oncol; 2007 Oct; 25(30):4707-13. PubMed ID: 17947717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.
    Horowitz NS; Wright AA
    Gynecol Oncol; 2015 Jul; 138(1):201-6. PubMed ID: 25870918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
    Furlanetto J; Eiermann W; Marmé F; Reimer T; Reinisch M; Schmatloch S; Stickeler E; Thomssen C; Untch M; Denkert C; von Minckwitz G; Lederer B; Nekljudova V; Weber K; Loibl S; Möbus V
    Ann Oncol; 2016 Nov; 27(11):2053-2059. PubMed ID: 27502721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelosuppression by chemotherapy in obese patients with gynecological cancers.
    Kamimura K; Matsumoto Y; Zhou Q; Moriyama M; Saijo Y
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):633-41. PubMed ID: 27485538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
    Griggs JJ; Mangu PB; Anderson H; Balaban EP; Dignam JJ; Hryniuk WM; Morrison VA; Pini TM; Runowicz CD; Rosner GL; Shayne M; Sparreboom A; Sucheston LE; Lyman GH;
    J Clin Oncol; 2012 May; 30(13):1553-61. PubMed ID: 22473167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacology of the taxanes: implications of the differences.
    Gligorov J; Lotz JP
    Oncologist; 2004; 9 Suppl 2():3-8. PubMed ID: 15161985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).
    Hunter RJ; Navo MA; Thaker PH; Bodurka DC; Wolf JK; Smith JA
    Cancer Treat Rev; 2009 Feb; 35(1):69-78. PubMed ID: 18922643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
    Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
    Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of the taxanes including nab-paclitaxel.
    Joerger M
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):691-702. PubMed ID: 25394848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy dosing in overweight and obese patients with cancer.
    Lyman GH; Sparreboom A
    Nat Rev Clin Oncol; 2013 Aug; 10(8):451-9. PubMed ID: 23856744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies.
    Durand C; Bylo M; Howard B; Belliveau P
    Ann Pharmacother; 2018 Jun; 52(6):580-590. PubMed ID: 29262697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body surface area as a determinant of pharmacokinetics and drug dosing.
    Sawyer M; Ratain MJ
    Invest New Drugs; 2001 May; 19(2):171-7. PubMed ID: 11392451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
    de Graan AJ; Loos WJ; Friberg LE; Baker SD; van der Bol JM; van Doorn L; Wiemer EA; van der Holt B; Verweij J; Mathijssen RH
    Clin Cancer Res; 2012 Aug; 18(16):4425-32. PubMed ID: 22645049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review.
    Thimotheo Batista JP; Santos Marzano LA; Menezes Silva RA; de Sá Rodrigues KE; Simões E Silva AC
    Curr Med Chem; 2023; 30(9):1003-1028. PubMed ID: 35946096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.
    Raman R; Mott SL; Schroeder MC; Phadke S; El Masri J; Thomas A
    Clin Breast Cancer; 2016 Dec; 16(6):480-486. PubMed ID: 27431461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
    Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.